This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $430,604 to Imperial College of Science, Technology and Medicine in the United Kingdom to conduct research on the role of placental macrophages in cytomegalovirus (CMV) infection at the maternal-fetal interface. The key objectives are to: 1) investigate the temporal response of placental macrophages (Hofbauer...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $682,879 to The Medical College of Wisconsin, Inc. to conduct research on the impact of human cytomegalovirus (HCMV) infection on the development of human neural tissues. The key objectives of this 5-year project are to: (1) define the transcriptional and cellular disruptions to developing human neural cells...
This Federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $598,664 to the Research Institute at Nationwide Children's Hospital (RINCH) to conduct research on adaptive immune responses to congenital and postnatal cytomegalovirus (CMV) infection. The key objectives are to: 1) Identify pathways that inhibit Th1 cell responses after congenital CMV (cCMV) infection, by...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on the structural and antigenic characterization of the Human Cytomegalovirus (HCMV) glycoprotein B (gB). The $134,269 award, effective September 1, 2024 through August 31, 2027, will enable the Trustees of Tufts College (dba Tufts University School of Medicine) to determine the high-resolution...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $232,415 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of California, Davis (UC Davis) to develop and test a highly potent monoclonal antibody that can neutralize the cytomegalovirus (CMV)-encoded IL-10 immunomodulatory protein. The goal is to evaluate if this antibody can provide significant protection against primary CMV infection, either alone or in combination with...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), with CFDA Number 93.855 - Allergy and Infectious Diseases Research, provides up to $589,921 in funding to The Regents of the University of California, San Francisco (UCSF) to support research on how the fetus and placenta avoid rejection by the maternal immune system. The key objectives of this 5-year project include: 1) evaluating the role of glycan-specific IgM natural antibodies in...
This federal Project Grant award of $651,832.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research supports research to define how changes to the proteome by ATM-activated signaling and ICP0-mediated ubiquitination alter recruitment of proteins onto viral genomes to promote Herpes Simplex Virus (HSV) gene expression and replication. The project aims to elucidate the intersection of phosphorylation and ubiquitination...
This Project Grant award, valued at $417,729.00 and funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to establish in vitro cell models for studying the reactivation of inherited chromosomally integrated human herpesvirus 6 (ICIHHV-6). The primary awardee, the University of California, Davis (UC Davis), will generate induced pluripotent stem cells (iPSCs) and differentiate them...
This Project Grant award of $178,932 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to analyze cord blood Vγ9Vδ2 (Vδ2) T cell differentiation and function using advanced single-cell sequencing techniques. The primary awardee, the University of Maryland, Baltimore, will utilize Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-seq) and Assay for...
This $3,305,720 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant will fund research to define the impact of maternal viral infections and inflammation on immune programming within the fetal brain and lymphoid organs in a non-human primate (NHP) model. The key objectives are to: 1) Use an ex vivo microculture model to determine innate immune pathways activated by...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $365,608 to Duke University to conduct research aimed at 1) identifying factors that restrict human cytomegalovirus (HCMV) replication in trophoblasts, the predominant cell type in the placenta, and 2) defining the impacts of HCMV-induced expression of the transcription factor DUX4 on normal trophoblast function. The research utilizes trophoblast organoids as a model system to better understand how HCMV can cross the placental barrier and either directly or indirectly damage the developing fetus. The objectives are to uncover cell-intrinsic trophoblast defenses against HCMV and elucidate how HCMV infection may impair critical trophoblast functions, with the goal of advancing scientific knowledge and potentially informing the development of interventions to prevent congenital HCMV infection and associated developmental complications.